Paterson Caroline

Biography

Caroline Paterson was appointed as the Lead Clinical Trials Nurse in the Medicines Monitoring Unit and Hypertension Research Centre, School of Medicine (Cardiovascular and Diabetes Medicine) University of Dundee, Ninewells Hospital and Medical School in June 2014. She qualified as a Registered General Nurse (RGN) in 1982. She completed the Orthopaedic Nursing Certificate (ONC) in 1983 at Phillipshill Hospital and the Victoria Infirmary in Glasgow and completed the Critical Care Course (CCC) in 1985 at the Western Infirmary in Glasgow. She completed a Diploma in Advanced Nursing Practice in 1991 and a BSc in Advanced Nursing Practice at Queen Margaret University in Edinburgh in 1994. She completed the Managing Safely Course awarded by the Institute of Occupational Safety and Health in 2001. She completed an MSc in Environmental and Occupational Medicine (By research) at the University of Aberdeen in 2011. From 1982, she worked as a Registered General Nurse in the following areas: General Surgery; Accident and Emergency; Elective, Trauma, Bone Infection, Rehabilitation Orthopaedics; Rheumatology; Spinal Injury; Neurology; Neurosurgery; General Intensive Care; Cardiothoracic Intensive Care; Renal Intensive Care; and Coronary Care in the UK and USA. From 2009 to 2010, she worked in Biomedical Research Institute / Tayside Tissue Bank undertaking the OVARIAN CANCER, BREAST CANCER CAMPAIGN, HAMMAN, FAST and IMPORT Studies. From 2010, she worked as a Clinical Research Nurse in the Clinical Research Centre and in The Division of Medical Sciences. Centre for Cardiovascular & Lung Biology, Vascular & Inflammatory Disease Research Unit. Ninewells Hospital and Medical School in Dundee, undertaking research on behalf of the University of Dundee in NHS Tayside, NHS Fife, NHS Lothian, NHS Greater Glasgow, NHS North Lanarkshire and NHS Luton and Dunstable. She has worked on the following studies TRACE RA, TRACE RA DAS, TRACE RA BIOBANK, ACT TAPER, PRED 4, PRED 5, set up The Scottish Lupus Exchange (SLEx) Scottish Lupus Database and assisted with the ALL ACS, ORBIT, ASCOT 10, SCOT, PATHWAY 1,2 3 Studies, SHARE and GO SHARE. She is currently working on the FAST, ALL HEART, TIME, FOURIER and PARAGON Studies in primary and secondary care, She has a particular interest in research and teaching. Her research interests include cardiology, hypertension, rheumatology, connective tissue disease, inflammatory bowel disease and occupational health diseases, with a particular interest in stress, backpain and mesothelioma. She holds honorary contracts / letters of access with all health boards in NHS Scotland and NHS England. 

Research Interest

CURRENT: ·         ALL HEART STUDY (Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease). ·         FAST STUDY (Febuxostat versus Allopurinol Streamlined Trial). ·         TIME STUDY (Treatment in Morning versus Evening). ·         FOURIER STUDY (A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy InPatients with Clinically Evident Cardiovascular Disease). ·         PARAGON STUDY (A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction). PREVIOUS: ·         PATHWAY 1 STUDY (Pathway 1: Monotherapy vs Dual Therapy for Initial Treatment for Hypertension). ·         PATHWAY 2 STUDY (Pathway 2: Prevention and treatment of hypertension with algorithm based therapy). ·         PATHWAY 3 STUDY (Pathway 3: A multicentre phase 4 study of comparison of single and combination diuretics in low-rennin hypertension). ·         SCOT STUDY (Standard Care versus Celecoxib Outcome Trial). ·         ASCOT 10 STUDY (Anglo-Scandinavian Cardiac Outcomes Trial; Post Trial Follow-Up Study). ·         The Scottish Lupus Exchange (SLEx) Scottish Lupus Database. ·         TRACE RA STUDY (Trace RA Trial, Trace RA DAS Study, Trace RA Biobank Study. Trial of Atorvasatin for the primary prevention of cardiovascular events in rheumatoid arthritis). ·         ACT TAPER STUDY (Roche Protocol ML28096 - A Randomised, phase IV, placebo controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA) who have demonstrated an inadequate response to prior disease modifying anti rheumatic drugs (DMARD’s) treatment and have initiated ROACTEMRA® (TOCILIZUMAB, TCZ) in combination with MTX). ·         PRED 4 STUDY (Predicting serious drug side effects in gastroenterology). ·         PRED 5 STUDY (Predicting 5 aminosalicylate nephrotoxicity in patients with inflammatory bowel disease). ·         ORBIT STUDY (Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy). ·         ALL ACS STUDY (Allopurinol in Acute Coronary Syndrome). ·         SYSTEMIC SCLEROSIS STUDY (Phase II/III Multicentre, randomised, double blind, placebo controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis).